---
title: "Medicus Pharma wins FDA backing for optimized Phase 2 Teverelix study in acute urinary retention"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292898007.md"
description: "Medicus Pharma received FDA written feedback supporting an optimized Phase 2 study of Teverelix for acute urinary retention. The redesigned protocol reduces enrollment from approximately 390 to 126 patients to generate earlier pharmacodynamic signals. The randomized, double-blind trial evaluates long-acting GnRH antagonist Teverelix DP via intramuscular and subcutaneous regimens, targeting prostate volume reduction and urinary function improvements."
datetime: "2026-07-16T11:30:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292898007.md)
  - [en](https://longbridge.com/en/news/292898007.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292898007.md)
---

# Medicus Pharma wins FDA backing for optimized Phase 2 Teverelix study in acute urinary retention

-   Medicus received FDA written feedback backing an optimized Phase 2 Teverelix study in acute urinary retention; FDA response dated July 8, 2026. \* Protocol redesign cuts planned enrollment to about 126 patients from about 390, aiming to generate an earlier pharmacodynamic signal. \* ANT-2111-02 is randomized, double-blind, placebo-controlled; tests long-acting GnRH antagonist Teverelix DP via intramuscular and subcutaneous regimens. \* Primary endpoint targets reduction in total prostate volume; study also tracks recurrent acute urinary retention plus urinary function measures. \* Central IRB Advarra cleared the protocol with modifications on June 18, 2026, supporting site activation and study start-up work. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160730PRIMZONEFULLFEED9763293) on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MDCX.US](https://longbridge.com/en/quote/MDCX.US.md)
- [MDCXW.US](https://longbridge.com/en/quote/MDCXW.US.md)

## Related News & Research

- [EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi](https://longbridge.com/en/news/294506242.md)
- [EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline](https://longbridge.com/en/news/282836614.md)
- [TE: Strong 2025 results, high TSR, and a €25bn backlog drive growth and shareholder value](https://longbridge.com/en/news/294971013.md)
- [17:35 ETPROCEPT BioRobotics Corporation Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit](https://longbridge.com/en/news/294876287.md)
- [Pirelli announces half-year financial report as of June 30, 2026 filed for public access](https://longbridge.com/en/news/294538982.md)